Form 4: Cidara Therapeutics Director Granted 11,100 Stock Options

Cidara Therapeutics, Inc. director Theodore R. Schroeder was granted 11,100 stock options with an exercise price of $21.31, vesting by June 2026 or the 2026 annual meeting.

Summary

• Theodore R. Schroeder, a Director of Cidara Therapeutics, Inc. (CDTX), was granted 11,100 stock options.
• The options have an exercise price of $21.31 per share.
• The transaction occurred on June 18, 2025.
• The options will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• The options expire on June 17, 2035.
• Following this transaction, Mr. Schroeder beneficially owns 11,100 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) to a director, which is generally a neutral to slightly positive event as it aligns director incentives with shareholder interests. There are no negative disclosures.

Positives

• Granting stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The grant of 11,100 options indicates continued commitment and involvement of a key board member.

Future Outlook

The vesting schedule indicates a future commitment period for the director, aligning their incentives with the company's performance through at least mid-2026.

Industry Context

This is a routine compensation event for a director in a publicly traded company, common across various industries, including biotechnology/pharmaceuticals where Cidara Therapeutics operates. It reflects standard corporate governance practices for incentivizing board members.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, similar to companies like Gilead Sciences, Amgen, or Pfizer, to align director interests with long-term shareholder value.
• The specific number of options and exercise price would need to be compared against peer companies' compensation structures and the company's market capitalization to assess if it's within typical ranges, but this document alone does not provide enough context for a detailed comparative assessment.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Cidara Therapeutics, CDTX, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Theodore R Schroeder